AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.
New data suggests that the United States’ increased focus on research security in recent years may be weakening its competitive advantage over China. Until around 2018, when the U.S. began increasing ...
Global health faces unprecedented strain and challenges to its legitimacy. The health-related Sustainable Development Goals and progress towards universal health coverage are off track, and ...
China’s rise in science has been even more dramatic than its rapid economic development. China and the United States currently spend far more on research and development and publish significantly more ...
Out of five critical tech sectors, "China has the most immediate opportunity to overtake the United States in biotechnology," the Harvard Belfer Center said in a new report. Just as China is ...
Opinion
2dOpinion
China’s 15th Five-Year Plan ‘exhibits flexibility and adaptation in pursuing longer-term objectives’
Editor's Note: 2026 marks the commencement of China's 15th Five-Year Plan (2026-30), a pivotal phase in the nation's medium- to long-term development. A ...
By Andrew MacAskill and Maggie Fick BEIJING/LONDON, Jan 29 (Reuters) - UK drugmaker AstraZeneca will invest $15 billion in ...
For decades, the United States held unrivalled global leadership in science and technology, based on its world-class research universities, high levels of public and private investment, and a policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results